III期非小细胞肺癌中C-12的检测及其预后意义

Detection of multiple tumor marker protein biochip and its prognostic significance in non-small cell lung cancer patients in stage III.

目的探讨多种肿瘤标志物蛋白芯片检测系统(C-12)在III期非小细胞肺癌的病情监测、治疗反应观察和预后评估中的意义。方法应用该芯片检测系统测定57例III期非小细胞肺癌病人化疗前后血清中12种肿瘤标志物(CA19-9,NSE,CEA,CA242,Fe,HCG,AFP,FPSA,PSA,CA125,HGH,CA15-3)的水平,观察化疗疗效与C-12的关系。结果57例病人中不同疗效组患者自身前后对照,其血清肿瘤标志物水平和C-12总阳性率无显著性差异;在剔除各组中C-12阴性病例后,PR组中的C-12阳性病人治疗后有CA19-9、CA15-3及Fe显著性降低(P<0.05),而NC组中的C-12阳性病人各项肿瘤标志物水平在化疗后均无明显变化。结论该检测系统在监测C-12阳性肺癌的治疗效果方面有一定的指导意义,如作适当改进,将能更有效地运用于临床。

Objective To investigate the significance of multiple tumor marker protein biechip detective system in monitoring therapeutic efficacy and evaluating prognosis in non - small cell lung cancer patients in stage Ⅲ. Methods From March 2003 to December 2004, 57 cases of non - small cell lung cancer patients in stage Ⅲ were investigated. All cases underwent chemotherapy, before and after treatment, the serum levels of 12 tumor markers（ C - 12） including CA19-9,NSE,CEA,CA242, Fe,HCG,AFP, FPSA,PSA,CA125,HGH and CA15-3, were measured , its relation to therapeutic efficacy was observed. Results Of the 57 treated patients, 27 patients had partial response （PR） and 21 patients had no change（ NC） ,9 patients had progressive disease（PD） ,but no patient had complete response（ CR）. There were no remarkable differences in serum levels of C - 12 after chemotherapy. After excluding the patients who were negative to C - 12, the serum levels of CA19 -9,CA15 -3 and Fe in PR group were significanter lower after chemotherapy （ P 〈 0.05 ） , but no remarkable difference in NC group. Conclusion The multiple tumor marker protein biochip detective system may play a role in monitoring therapeutic efficacy in C - 12 positive lung cancer , it maybe a useful monitor marker to C - 12 positive lung cancer patients.